Lupus & antiphospholipid syndrome

Insights into the 2023 ACR/EULAR antiphospholipid syndrome classification criteria: findings from a cohort of 205 patients with primary antiphospholipid syndrome (APS)

Rheumatology (Oxford)Published Retrospective cohort study

Authors' conclusion

Among PAPS patients classified by Sydney criteria, 16.6% did not meet 2023 ACR/EULAR criteria. One quarter of them had a thrombotic relapse, confirming a pro-thrombotic profile.

Study context

Population
Primary vascular APS (PAPS) patients meeting the Sydney criteria with previous vascular manifestations, followed 1992–2023
Participants
205 participants
Exposure
PAPS patients meeting vs not meeting the 2023 ACR/EULAR APS classification criteria
  • Met ACR/EULAR criterian = 171reference
  • Did not meet ACR/EULAR criterian = 34
Outcome
Performance of the 2023 ACR/EULAR criteria (proportion of Sydney-classified PAPS not classified)
Methodological detailsre-classification of Sydney-classified PAPS by 2023 ACR/EULAR criteria
  • Re-classification of Sydney-classified PAPS by 2023 ACR/EULAR criteria

Main finding

As reported in the abstract

Classification by 2023 ACR/EULAR criteria

Met ACR/EULAR criteria

171

events

Did not meet ACR/EULAR criteria

16.6%

34

Not met due to isolate IgM positivity
23
Not met due to aPL titer >99th percentile but <40 units
11

Observational data: associations, not effects.

Further findings

OutcomeValues
Thrombotic relapse during follow-up in patients not confirmed as PAPS by 2023 ACR/EULAR criteriaNot confirmed as PAPS 26%
  • Thrombotic relapse during follow-up in patients not confirmed as PAPS by 2023 ACR/EULAR criteria: 9/34

Thrombotic recurrence, fulfilled vs not the new criteria

Rate of thrombotic recurrence similar between patients who fulfilled or not the new criteria

Original publication

Insights into the 2023 ACR/EULAR antiphospholipid syndrome classification criteria: findings from a cohort of 205 patients with primary APS. Rheumatology (Oxford). Published 17 December 2024. doi:10.1093/rheumatology/keae665

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.